2Lamba JK,Lin YS,Schuetz EG,et al.Genetic contribution to variable human CYP3A mediated metabolism[J].Adv Drug Deliv Rev,2002;54:1271-1294.
3Peebles KA,Baker RK,Kurz EU,et al.Catalytic inhibition of human DNA topoisomerase Ⅱ alpha by hypericin,a naphthodianthrone from St.John's wort (Hypericum perforatum)[J].Biochem Pharmacol,2001;62:1059-1070.
4Mansky PJ,Straus SE.St.John's Wort:More implications for cancer patients[J].J Natl Cancer Inst,2002;94:1187-1188.
5Beijnen JH,Schellens JH.Drug interactions in oncology[J].Lancet Oncol,2004;5:489-496.
6Sparreboom A,Danesi R,Ando Y,et al.Pharmacogenomics of ABC transporters and its role in cancer chemotherapy[J].Drug Resist Updat,2003;6:71-84.
7Bosch TM,Meijerman I,Beijnen JH,et al.Genetic polymorphisms of drug metabolizing enzymes and drug transporters in the chemotherapeutic treatment of cancer[J].Clin Pharmacokinet,2006;45:253-285.
8Sparreboom A,Cox MC,Acharya MR,et al.Herbal remedies in the United States:potential adverse interactions with anticancer agents[J].J Clin Oncol,2004;22:2489-2503.
9Schinkel AH,Jonker JW.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family:an overview[J].Adv Drug Deliv Rev,2003;55:3-29.
10Richardson MA,Sanders T,Palmer JL,et al.Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology[J].J Clin Oncol,2000;18:2505-2514.
